Cover Image

SGLT-2 inhibitors in heart failure: a literature review on mechanisms, efficacy and safety

Introduction: Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors), known as flozins, are a recent class of medications gaining recognition for their effectiveness in diabetes, cardiovascular health, and heart failure management. The objective of this study is to examine and integrate recent...

Full description

Saved in:

Bibliographic Details
Main Authors:	Klaudia Kułak (Author), Katarzyna Chamera-Cyrek (Author), Izabela Janik (Author), Martyna Kuśmierska (Author), Anna Koman (Author), Marzena Pliszka (Author), Katarzyna Gadżała (Author), Karolina Palacz (Author), Izabela Sztybór (Author), Sabina Przygodzka (Author)
Format:	Book
Published:	Nicolaus Copernicus University in Toruń, 2024-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Increasing Occurrence of Infectious Diseases in Childhood: Is It Linked with Declining Vaccination Rates Across Society?
by: Izabela Sztybór, et al.
Published: (2024)

Ozempic (semaglutide) - review of pharmacological properties, mechanism of action and clinical applications
by: Anna Maria Koman, et al.
Published: (2024)

The Beneficial Effects of Aerobic Exercise on Human Systems and Organs: A Literature Review
by: Anna Maria Koman, et al.
Published: (2024)

Understanding the Challenges of Hashimoto's Thyroiditis: Perspectives on Diagnosis, Treatment, and Associated Conditions
by: Klaudia Brygida Kułak, et al.
Published: (2024)

Obesity - an epidemic of the 21st century - literature review
by: Klaudia Kułak, et al.
Published: (2024)

SGLT2 inhibitors - a breakthrough in treatment of heart failure and their multipotential beneficial role in cardiology, diabetology, nephrology and neurology
by: Marta Bogowska, et al.
Published: (2023)

The Impact of Creatine Supplementation on Strength Training
by: Izabela Janik, et al.
Published: (2024)

SGLT2-Inhibitors - significant role in Heart Failure treatment
by: Karol Wielgus, et al.
Published: (2024)

SGLT-2 inhibitors in the management of acute decompensated heart failure
by: Anastasia E. Poskakalova, et al.
Published: (2024)

SGLT-2 inhibitors: new effective drugs for treatment of heart failure
by: Olgierd Król, et al.
Published: (2022)

Emerging concepts in heart failure treatment and management: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
by: Andrea Beatriz De Lorenzi, et al.
Published: (2023)

The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective
by: Saverio Muscoli, et al.
Published: (2022)

Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria
by: Yixiang Xu, et al.
Published: (2023)

IMPROVING PRESCRIPTION OF SGLT-2 INHIBITORS IN HEART FAILURE MANAGEMENT AT UT TYLER INTERNAL MEDICINE RESIDENT CLINIC
by: Mariam Qazi, DO, et al.
Published: (2023)

SGLT2 inhibitors for patients with heart failure with preserved ejection fraction in China: a cost-effectiveness study
by: He Lu, et al.
Published: (2023)

The use of SGLT2 inhibitors in the treatment of cognitive disorders
by: Marta Lato, et al.
Published: (2023)

Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China
by: Yaohui Jiang, et al.
Published: (2021)

The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy
by: Klaudia Kowalska, et al.
Published: (2022)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors Use among Heart Failure Patients and the Role of Pharmacists in Early Initiation of Therapy
by: Mohammed Aldhaeefi, et al.
Published: (2023)

Understanding the Mechanisms and Treatment of Heart Failure: Quantitative Systems Pharmacology Models with a Focus on SGLT2 Inhibitors and Sex-Specific Differences
by: Jean François Ndiaye, et al.
Published: (2023)

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
by: Zofia Wicik, et al.
Published: (2022)

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
by: Yu Zhang, et al.
Published: (2023)

Pretreatment with KGA-2727, a selective SGLT1 inhibitor, is protective against myocardial infarction-induced ventricular remodeling and heart failure in mice
by: Yohei Sawa, et al.
Published: (2020)

SGLT-2 inhibitors: Post infarction interventional effects
by: Pugazhenthan Thangaraju, et al.
Published: (2023)

SGLT2 inhibitors and the changing landscape for treatment of diabetes
by: Liu S, et al.
Published: (2019)

SGLT2 inhibitors: control of glycemia and nephroprotection properties
by: A. A. Volodin, et al.
Published: (2018)

SGLT2 inhibitors: suggestions from the amphibian world
by: Stefano Michelassi
Published: (2022)

SGLT2 Inhibitors and Fracture Risk in Elderly Population
by: Vishal R Tandon, et al.
Published: (2023)

Impact of SGLT2 inhibitors treatment on the chronic kidney disease in people with type 2 diabetes
by: Marcin Czarkowski, et al.
Published: (2022)

Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
by: Kai-Fan Tsai, et al.
Published: (2021)

Reply to SGLT-2 inhibitors: Post-infarction interventional effects
by: Pasquale Paolisso, et al.
Published: (2023)

SGLT2-inhibitors are effective and safe in the elderly: The SOLD study
by: Maria Elena Lunati, et al.
Published: (2022)

Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases
by: Runfang Pan, et al.
Published: (2024)

The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition
by: Muhammad Saad, et al.
Published: (2018)

Sotagliflozin, an inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1/2), as a new therapeutic approach for patients with type 1 diabetes mellitus
by: Mirella Czapska, et al.
Published: (2018)

Sotagliflozin, an inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1/2), as a new therapeutic approach for patients with type 1 diabetes mellitus
by: Mirella Czapska, et al.
Published: (2018)

Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus
by: Lea El Hage MD, et al.
Published: (2019)

Analysis of efficacy of SGLT2 inhibitors using semi-mechanistic model
by: Oleg eDemin Jr, et al.
Published: (2014)

Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor
by: T. M. Bukatina, et al.
Published: (2018)

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
by: Nauck MA
Published: (2014)